UCB's Global Corporate Website
Welcome to UCB in the United States

May

31

Go Behind The Mystery of Myasthenia Gravis On Myasthenia Gravis Awareness Month

May

31

Empowering the Hidradenitis Suppurativa Community: UCB's Triple Approach

May

23

UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

May

10

Moms Really Can Do It All - Meet Tracy: a Mom, Caregiver, Neuroscientist, and Advocate in the Rare Disease Community

May

06

Evolving Expectations for Arthritis Management